1. Home
  2. RMCO vs FLNA Comparison

RMCO vs FLNA Comparison

Compare RMCO & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Royalty Management Holding Corporation

RMCO

Royalty Management Holding Corporation

N/A

Current Price

$2.03

Market Cap

35.2M

Sector

Miscellaneous

ML Signal

N/A

FLNA

Filana Therapeutics Inc. Common Stock

SELL

Current Price

$0.64

Market Cap

30.0M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RMCO
FLNA
Founded
2021
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
35.2M
30.0M
IPO Year
2021
2000

Fundamental Metrics

Financial Performance
Metric
RMCO
FLNA
Price
$2.03
$0.64
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
★ $6.50
AVG Volume (30 Days)
9.2K
★ 462.6K
Earning Date
11-13-2026
11-05-2026
Dividend Yield
★ 0.49%
N/A
EPS Growth
N/A
★ N/A
EPS
★ N/A
N/A
Revenue
$4,949,916.00
★ $41,119,000.00
Revenue This Year
$61.62
N/A
Revenue Next Year
$62.50
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 513.30
N/A
52 Week Low
$1.74
$0.39
52 Week High
$5.00
$2.03

Technical Indicators

Market Signals
Indicator
RMCO
FLNA
Relative Strength Index (RSI) 40.15 55.81
Support Level $1.90 $0.43
Resistance Level $2.46 $0.68
Average True Range (ATR) 0.14 0.06
MACD -0.00 0.02
Stochastic Oscillator 38.00 93.03

Price Performance

Historical Comparison
RMCO
FLNA

About RMCO Royalty Management Holding Corporation

Royalty Management Holding Corp is formed to invest or purchase assets that have near and medium-term income potential to provide RMC with accretive cash flow from which it can reinvest in new assets or expand cash flow from those existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.

About FLNA Filana Therapeutics Inc. Common Stock

Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.

Share on Social Networks: